# Ann Lin

> Ann Lin is the co-founder and CEO of Cromatic, an AI-native RevOps platform that helps life-science companies find and manage contract research organizations (CROs). A Stanford genetics PhD and Forbes 30 Under 30 (Science, 2020) honoree, she made her name in the lab of Jason Sheltzer at Cold Spring Harbor, where her team showed that a celebrated cancer drug did not hit its supposed target. After scientifically co-founding the drug-discovery startup Meliora Therapeutics, she turned a Google Sheet of outsourcing complaints into a company, raising a $5.3M seed round in 2023 to fix the notoriously opaque market for biotech R&D vendors.

- **Role:** Co-Founder & CEO at Cromatic
- **Organizations:** Cromatic, Meliora Therapeutics, Cold Spring Harbor Laboratory, Stanford University
- **From:** Flushing, New York, United States
- **Nationality:** American
- **Education:** PhD, Genetics, Stanford University, BA/BS, Biochemistry and Economics, Stony Brook University
- **Known for:** Forbes 30 Under 30 (Science), 2020, Co-authored research revealing a cancer drug worked through an unintended mechanism, reshaping how on-target activity is verified, Scientific co-founder of Meliora Therapeutics

## Career timeline

- **undergrad** — Interned in Jason Sheltzer's lab at Cold Spring Harbor Laboratory while a Stony Brook undergraduate
- **2019** — Co-authored research showing the cancer drug target MELK was not the actual mechanism of a drug in trials
- **2020** — Named to the Forbes 30 Under 30 list (Science) at age 23
- **2020s** — Scientific co-founder and advisor of Meliora Therapeutics, with mentor Jason Sheltzer
- **Norway** — Fulbright Scholar building an Organ-on-CHIP and mass-spectrometry platform to quantify drug response in real time
- **2022** — Co-founded Cromatic with CTO Anne Chen (ex-Meta engineer); incorporated May 2022
- **2023** — Began onboarding biotech clients in January; raised $5.3M seed round in November
- **2024** — Launched Sourcerer, an AI-powered CRO/CDMO vendor-discovery tool, on June 20

## Achievements

- Forbes 30 Under 30 (Science), 2020
- Co-authored research revealing a cancer drug worked through an unintended mechanism, reshaping how on-target activity is verified
- Scientific co-founder of Meliora Therapeutics
- Co-founded and leads Cromatic, raising a $5.3M seed round
- Fulbright Scholar in Norway

## Latest updates

- **2024-06** — Launched Sourcerer, an AI vendor-discovery tool that reads multi-page RFPs to match companies with CROs and CDMOs.
- **2023-11** — Closed a $5.3M seed round led by AgFunder and LifeX, with Accel, Kleiner Perkins, Lux Capital, and FJ Labs.

## Links

- Website: https://cromatic.bio
- LinkedIn: https://www.linkedin.com/in/ann-lin-94a447111/
- Twitter/X: https://twitter.com/cromatichq

---

Profile page: https://yespress.io/ann-lin
Published by YesPress — https://yespress.io
Last updated: 2026-06-25